<![CDATA[BeiGene, Ltd. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=38815>Tue, 17 Mar 2026 17:20:52 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[BeiGene Presents Pioneering Cancer Research at ASCO 2025 - Redefining Treatment Across Hematology and Solid Tumors]]>https://www.newswire.co.kr/newsRead.php?no=1011839Sun, 25 May 2025 14:25:00 +0900<![CDATA[베이진, ASCO 2025에서 암 연구 결과 발표… 혈액학 및 고형 종양 치료 재정의]]>https://www.newswire.co.kr/newsRead.php?no=1011840Sun, 25 May 2025 14:25:00 +0900<![CDATA[BeiGene Announces First Quarter 2025 Financial Results and Business Updates]]>https://www.newswire.co.kr/newsRead.php?no=1010859Fri, 09 May 2025 15:10:00 +0900<![CDATA[베이진, 2025년 1분기 실적 및 비즈니스 업데이트 발표]]>https://www.newswire.co.kr/newsRead.php?no=1010862Fri, 09 May 2025 15:10:00 +0900<![CDATA[U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene]]>https://www.newswire.co.kr/newsRead.php?no=1010593Tue, 06 May 2025 12:20:00 +0900<![CDATA[미국 특허상표청, 베이진에 대한 파마사이클릭스 특허 무효화]]>https://www.newswire.co.kr/newsRead.php?no=1010594Tue, 06 May 2025 12:20:00 +0900<![CDATA[BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program]]>https://www.newswire.co.kr/newsRead.php?no=1009163Thu, 10 Apr 2025 11:40:00 +0900<![CDATA[베이진, 오시퍼리맙 임상 개발 프로그램에 대한 최신 정보 제공]]>https://www.newswire.co.kr/newsRead.php?no=1009165Thu, 10 Apr 2025 11:40:00 +0900<![CDATA[BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates]]>https://www.newswire.co.kr/newsRead.php?no=1007043Fri, 07 Mar 2025 13:30:00 +0900<![CDATA[베이진, 2024년 4분기 및 연간 재무 실적과 비즈니스 업데이트 발표]]>https://www.newswire.co.kr/newsRead.php?no=1007044Fri, 07 Mar 2025 13:30:00 +0900<![CDATA[BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference]]>https://www.newswire.co.kr/newsRead.php?no=1003485Tue, 24 Dec 2024 10:35:00 +0900<![CDATA[베이진, 1월 2일 나스닥 티커 심볼을 ‘ONC’로 변경… 제43회 연례 J.P. 모건 헬스케어 콘퍼런스에 참석]]>https://www.newswire.co.kr/newsRead.php?no=1003486Tue, 24 Dec 2024 10:35:00 +0900<![CDATA[BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets]]>https://www.newswire.co.kr/newsRead.php?no=1002724Thu, 12 Dec 2024 15:00:00 +0900<![CDATA[베이진, ASH 2024에서 브루킨사A® 및 노벨 파이프라인 에셋(Novel Pipeline Assets)을 포함한 혈액학 프랜차이즈의 새로운 데이터로 CLL의 리더십 향상]]>https://www.newswire.co.kr/newsRead.php?no=1002725Thu, 12 Dec 2024 15:00:00 +0900<![CDATA[BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer]]>https://www.newswire.co.kr/newsRead.php?no=1000964Sun, 17 Nov 2024 15:40:00 +0900<![CDATA[베이진, 사명을 ‘비원 메디신스’로 변경하고 암 퇴치 위한 글로벌 커뮤니티 단합의 임무 재확인]]>https://www.newswire.co.kr/newsRead.php?no=1000965Sun, 17 Nov 2024 15:40:00 +0900<![CDATA[BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates]]>https://www.newswire.co.kr/newsRead.php?no=1000913Fri, 15 Nov 2024 13:50:00 +0900<![CDATA[베이진, 2024년 3분기 재무 결과 및 기업 업데이트 발표]]>https://www.newswire.co.kr/newsRead.php?no=1000914Fri, 15 Nov 2024 13:50:00 +0900<![CDATA[BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024]]>https://www.newswire.co.kr/newsRead.php?no=1000277Thu, 07 Nov 2024 10:15:00 +0900<![CDATA[베이진, ASH 2024에서 B세포 악성 종양 전반에 걸친 혁신적인 혈액학 포트폴리오 강조]]>https://www.newswire.co.kr/newsRead.php?no=1000278Thu, 07 Nov 2024 10:15:00 +0900<![CDATA[BeiGene Mourns Death of Beloved Board Member Donald Glazer]]>https://www.newswire.co.kr/newsRead.php?no=999549Tue, 29 Oct 2024 13:50:00 +0900<![CDATA[베이진, 이사회 멤버 도널드 글레이저의 사망 애도]]>https://www.newswire.co.kr/newsRead.php?no=999552Tue, 29 Oct 2024 13:50:00 +0900<![CDATA[BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma]]>https://www.newswire.co.kr/newsRead.php?no=999237Thu, 24 Oct 2024 10:00:00 +0900<![CDATA[베이진, 진행성·전이성 위 또는 위식도 접합부암 및 식도 편평상피세포암 1차 치료제로 ‘TEVIMBRA®’에 대해 CHMP서 긍정적 의견 획득]]>https://www.newswire.co.kr/newsRead.php?no=999241Thu, 24 Oct 2024 10:00:00 +0900<![CDATA[글로벌 종양학 혁신 기업 베이진, 샬리니 샤프를 이사에 임명]]>https://www.newswire.co.kr/newsRead.php?no=997631Fri, 27 Sep 2024 14:20:55 +0900